Insulet Corporation PODD
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending clarity on US retention and Q3 results.
Strong fundamentals and profitability are weighed against lowered US guidance and execution risks, supporting a cautious stance.
The market focuses on the lowered guidance and execution risks around type 2 retention, creating strongly negative momentum.
HOLD is the call. Negative is the market mood. High risk means a lot can go wrong.
Latest change
- 5 Nov 2026 — The report was released on 4 November and showed stronger-than-expected results, driving the stock sharply higher on high volume.
About the company
Insulet develops and sells tubeless insulin pumps under the Omnipod brand. The company is profitable with strong growth but recently lowered its US outlook due to onboarding issues for type 2 patients.
Bull case
International expansion and Omnipod 5 growth can offset weaker US sales.
Bear case
Lowered US guidance, recalls and class actions create ongoing uncertainty and negative momentum.
Why this signal
Strong fundamentals and profitability are weighed against lowered US guidance and execution risks, supporting a cautious stance.
Recent news
Insulet reported Q3 2026 on 4 November with revenue of 842 M USD (+19.2 % YoY) and net income of 141.1 M USD, beating estimates. The board approved a 1 billion USD share repurchase program. Management flagged lower growth in 2027 due to rising competition.